![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 14, 10308-10314, April 7, 2000
From the Departments of a Bone and Cartilage Biology, c Molecular Biology, e Protein Biochemistry, f Toxicology, g Pulmonary Pharmacology, h Immunology, i Molecular Virology and Host Defense, and j Structural Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
| |
ABSTRACT |
|---|
|
|
|---|
Interleukin-1 (IL-1), fibroblast growth factors
(FGFs), and their homologues are secreted factors that share a common
The interleukin
(IL)1-1/fibroblast growth
factor (FGF) family is a growing family of proteins that share a common
While the overall folds of the ligands and receptor extracellular
domains have been maintained evolutionarily, the family has evolved
into two distinct arms, the IL-1s and the FGFs, which show no
significant sequence homology and have distinct biological properties.
The limited sequence homology is also seen between IL-1 family members
and results from the small number of internal residues required to
maintain the IL-1s activate their target receptors by bringing together two
different receptor subunits. IL-1 Cells, Cell Culture, and Reagents--
Human keratinocytes were
obtained from Clonetics (Walkersville, MD) and cultured in growth
medium supplied by the vendor. A431 cells were obtained from ATCC
(Manassas, VA) and grown in Dulbecco's modified Eagle's medium
containing 10% fetal calf serum. IL-1 Identification and Cloning of Novel IL-1
Homologues--
Potential full-length cDNAs corresponding to two
new members of the IL-1 family (IL-1H1 and IL-1H3) were initially
identified through a search of an assembled version of the public and
commercial EST data bases, respectively, using BLAST or FASTA and known
members of the IL-1 family. Two additional members (IL-1H2 and IL-1H4) were subsequently found by searching with complete sequences of IL-1H1
and IL-1H3, respectively. The cDNAs corresponding to these ESTs
were obtained from Human Genome Sciences (Gaithersburg, MD) (IL-1H1 and
IL-1H2) or the IMAGE consortium (mouse IL-1H3: accession no. W08205,
IMAGE clone no. 332733; IL-1H4: accession nos. AI014548 and AI343258,
IMAGE clone no. 1628761). Complete sequencing of these cDNAs showed
that they contained an entire coding region for each homologue. A
portion of the sequence of IL-1H1 matched with human STS
CHLC.GAAT11C03.P3330 clone GAAT11C03 (accession no. G942011), which has
been mapped to chromosome 2q approximately 142 centimorgans from the
end of the chromosome. A partial, aberrantly spliced mouse homologue of
IL-1H1 (accession no. AA030324) was identified in an assembled mouse
EST data base in a search with human IL-1H1. A correctly spliced mouse IL-1H1 cDNA homologue was obtained via reverse
transcriptase-polymerase chain reaction from RNA isolated from
TNF Expression and Purification--
The full-length cDNA
encoding IL-1H1 was subcloned into pET16B (Novagen Inc., Madison, WI)
vector at the NdeI site. To ensure an authentic N terminus
following factor Xa cleavage, removal of the NdeI site was
performed using the QuickChange System (Stratagene, La Jolla, CA)
according to the manufacturer's recommendations. Human IL-1 H1 was
then expressed as an N terminus His6-factor Xa-tagged
protein in Escherichia coli BL21(DE3) with 1 mM
isopropyl-1-thio- Circular Dichroism--
Circular dichroism data were measured on
a Jasco J-710 CD Spectropolarimeter at 0.3 mg/ml cytokine in a 0.1-cm
path length water-jacketed cuvette at 22 °C in 10 mM
sodium phosphate, 150 mM NaCl, 0.3 mM EDTA, pH
7.0. Wavelength scans were taken at 50 nm/min, and eight spectra were
averaged in each case. Concentrations of cytokines were determined by
absorbance at 280 nm using extinction coefficients calculated from
sequence (28). Thermal stability curves were measured by monitoring at
a single wavelength while raising scanning temperature at about 1 degree/min.
Northern and Western Blots and Immunoprecipitation--
Total
RNA was isolated from various cells and tissues using Trizol reagent
(Life Technologies Inc., Rockville, MD) according to the
manufacturer's recommendations. RNA was fractionated by electrophoresis on 1.2% agarose-formaldehyde gels, transferred to
GeneScreen Plus membranes, and cross-linked using a UV Stratalinker-180 (Stratagene). The blots were probed with 32P-labeled IL-1Hs
or IL-4 cDNA and the housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) according to standard procedures. A commercial
human and murine multiple tissue Northern blot
(CLONTECH, Palo Alto, CA), containing 2 µg of
poly(A)+ RNA from various tissues, was processed according
to the manufacturer's instructions.
For immunoblot analysis, cell lysates and conditioned media were
separated by SDS-polyacrylamide gel electrophoresis and transferred to
a nitrocellulose membrane, blocked with 5% nonfat dry milk in PBST
(PBS containing 0.1% Tween 20), and probed with anti-IL-1H1 antibody
or anti-HSV glycoprotein C R46 (generous gift of R. Eisenberg and G. Cohen) (29). The membrane was then washed and developed with
horseradish peroxidase-conjugated secondary antibody and ECL (Amersham
Pharmacia Biotech).
For immunoprecipitation, cells were metabolically labeled by incubating
exponentially growing cells for 4 h in methionine- and
cysteine-free medium containing 5% dialyzed FBS with 100-150 µCi/ml
of Tran35S-label (~1000 Ci/mmol, ICN Biomedicals, Costa
Mesa, CA). Cells were lysed in PBSTDS (PBS containing 10% Triton
X-100, 0.5% deoxycholate, and 0.1% SDS). Five µl of preimmune or
anti-IL-1H1 immune serum was then mixed with precleared
35S-labeled cell lysate or conditioned medium and 20 µl
of protein A-agarose (Life Technologies) and incubated overnight at
4 °C. Immunoprecipitates were collected by centrifugation and washed three times with lysis buffer. The beads were solubilized in sample buffer and resolved through SDS-polyacrylamide gel electrophoresis, fixed, dried, and processed for autoradiography.
In Vivo Models--
BALB/c mice (n = 6) were
treated with oxazolone as described previously (30). Briefly, mice were
sensitized on day 0 by a single application of 10 µl of a 1.6%
solution of oxazolone (Sigma) in ethanol on the left ear. To
characterize the early response to oxazolone, the animals were
challenged on day 7 with 10 µl of 0.8% solution of oxazolone on the
left ear. Ear thickness was measured with a dial micrometer (L. S. Starrett Co., Athol, MA), and tissue samples were collected at various
time points after challenge over a 24-h period. In the experiment of
repeated oxazolone challenges, the mice were challenged with 10 µl of
a 0.8% solution of oxazolone on the left ear three times per week for
4 weeks postsensitization (on days 7, 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, and 32). Ear thickness was measured, and tissue samples were
collected 24 h after each challenge. In addition, the established
chronic lesion at 4 weeks was examined at various time points up to
24 h after the last challenge. Mouse ears were exposed to UVB
radiation for 30 min as described previously (31).
For herpes simple virus (HSV) infection, 6-week-old female BALB/c mice
(Charles River, Raleigh, NC) (n = 4) were anesthetized by intraperitoneal injection of ketamine (40 mg/kg; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (5 mg/kg; Miles, Shawnee Mission, KS) and then inoculated, after ear pinna scarification, with
105 plaque-forming units of HSV-1 SC16 (32) diluted in PBS
containing 10% fetal calf serum. Animals were observed daily for signs
of infection. At various times postinfection, mice were euthanized using CO2 followed by exsanguination and removal of ear
pinnae. Samples for protein and RNA analysis were snap-frozen in liquid nitrogen. RNA was prepared using the Trizol method (Life Technologies). Protein extracts were prepared by homogenization in radioimmune precipitation buffer (Roche Molecular Biochemicals) as described by the
manufacturer. Ears were also processed for histological analysis. All
experiments involving animals were in accordance with SmithKline
Beecham's animal care and use committee recommendations.
In Situ Hybridization--
Mouse ears were immersion-fixed in
4% paraformaldehyde in PBS at 4 °C overnight, cryoprotected in 15%
sucrose in PBS overnight, and frozen-embedded in OCT compound
(TissueTek, Miles Inc., Elkhart, IN). Tissues were sectioned at 10 µm, deproteinated in 0.2 M HCl for 10 min, acetylated in
0.1 M triethanolamine with 0.25% acetic anhydride for 15 min, and dehydrated through a graded series of ethanols. Polymerase
chain reaction-generated murine IL-1H1 cDNA templates containing T7
and SP6 promoter sites were used for riboprobe generation, and in
situ hybridization was performed as described previously (33).
Following hybridization, the tissues were dehydrated through a series
of graded ethanols, air-dried, and developed by emulsion
autoradiography. Tissue sections were then stained with hematoxylin and
eosin for histological analysis.
Identification and Structural Analysis of Novel IL-1
Homologues--
A search of public and private EST data bases for
sequence homologues of the IL-1 family revealed four new members, which we have designated IL-1H1, IL-1H2, IL-1H3, and IL-1H4. Complete predicted sequences of the four proteins and their alignment with known
IL-1 family members is shown in Fig.
1A. The percentage amino acid
similarity of the IL-1Hs to known members of the family including IL-18
varies between 12 and 54%, which can be compared with the 28-36%
similarity seen among IL-1
IL-1H1 was mapped to chromosome 2q12-21, which is close to the region
where IL-1
A schematic representation of all IL-1 members is shown in Fig.
1B. Like all but one of the known IL-1 family members,
IL-1ra, the four IL-1Hs do not encode a hydrophobic leader peptide
found in most secreted proteins, and hence we would expect these
proteins to be released from cells undergoing necrosis or apoptosis.
Similar to the intracellular form of IL-1ra, IL-1H1, IL-1H2, and IL-1H3 lack a propeptide sequence, but their entire coding regions align with
the mature regions of IL-1
To further characterize and compare the properties of these new IL-1
homologues with the known IL-1 members, we initially focused on IL-1H1.
Upon expression of an amino-terminal His6-tagged fusion in
E. coli, IL-1H1 was found to be soluble, and it could be
purified through Ni2+-nitrilotriacetic acid chromatography.
Cleavage at the engineered factor Xa site yielded mature IL-1H1 (data
not shown).
Circular Dichroism and Thermal Stability Analyses--
To obtain
additional evidence that IL-1H1 was structurally similar to other
IL-1s, we compared its CD spectrum with that of IL-1ra and IL-1
Because it is similar in structure and site of synthesis to other
IL-1s, we expected that IL-1H1 might bind to a receptor in the IL-1R
family. However, we were unable to demonstrate any binding to the type
I IL-1R, IL-18R, or ST2/T1, suggesting that it binds to an as yet
unidentified receptor (data not shown).
Expression of Novel IL-1 Homologues--
No expression of any of
the novel homologues was detected in normal tissues represented on
commercially available multiple tissue blots, suggesting that the IL-1
homologues are either expressed at low levels or require suitable
stimulation. This is reflected by the rare occurrence of ESTs for the
homologues in public or commercial data bases. Thus, human IL-1H1 ESTs
were identified only in TNF
In situ hybridization of the mouse IL-1H1 cDNA to a
panel of normal mouse tissue sections revealed expression in only the esophageal squamous mucosa. Low levels of IL-1H1 expression
(~100-200 copies/ng of mRNA) were also detected in normal human
lung and macrophages by Taqman analysis (data not shown). These data
support the lack of widespread expression seen in the human multiple
tissue Northern blots. In contrast, IL-1H1 mRNA was found to be
induced in TNF
To evaluate changes in IL-1H1 protein levels, polyclonal antibodies
were raised to both human and murine IL-1H1. Both immunoprecipitation and Western blot demonstrate that IL-1H1 protein was induced in human
keratinocytes by TNF In Vivo Expression of IL-1H1 in Response to Inflammatory
Stimuli--
To explore the potential pathological role of
keratinocyte-expressed IL-1H1, we utilized a murine skin inflammation
and contact hypersensitivity model (CHS) (30). Mouse ears were
irradiated with UVB radiation for 30 min as described (31, 40) or
topically treated with oxazolone in an acute or chronic mode as
detailed under "Materials and Methods." UVB irradiation (31) and a
single oxazolone sensitization/challenge produced an acute inflammatory response but did not result in significant IL-1H1 induction (Fig. 4A). Mouse ears were also
treated in a chronic mode by repeated challenge with oxazolone after an
initial sensitization. In this model, exposure to oxazolone leads to a
delayed type hypersensitivity reaction. Initially there is a TH1-driven
immune response characterized by the presence of elevated TNF
To confirm that the differences between chronic and acute oxazolone
treatment were not due to differences in the kinetics of IL-1H1
induction, we treated mouse ears with oxazolone under acute and chronic
conditions and prepared RNA at 3, 6, and 24 h after the last
challenge. The expression of IL-1H1 was seen at all time points but
only after chronic oxazolone treatment and not under acute treatment
(Fig. 4B). These data suggest that the induction of IL-1H1
mRNA reflects underlying changes in the tissue caused by chronic
oxazolone treatment and not a response to each application. Consistent
with previous reports, the expression of IL-4 mRNA was also induced
only under chronic conditions (Fig. 4B and Ref. 30),
signaling a switch to a TH2 immune response. These data suggest that
the expression of IL-1H1 may be linked to CHS and/or a TH2-driven
immune response.
The cellular source of IL-1H1 mRNA in chronically oxazolone-treated
mouse ears was determined by in situ hybridization. As shown
in Fig. 5, IL-1H1 mRNA was expressed
in keratinocytes in the hyperplastic epithelium of ears from mice
chronically sensitized with oxazolone and harvested 24 h after the
last challenge (Fig. 5A). No signal was observed in control
experiments (Fig. 5, B-D).
These data suggest that IL-1H1 may play a role in CHS. Interestingly,
IL-1 itself has been implicated in CHS (41-43). However, results from
experiments in an il-1 Expression of IL-1H1 in Herpes Simplex Virus Infection--
HSV-1
is known to induce a number of cytokines during acute infection, and
HSV-1-infected keratinocytes have been implicated as a source of
several cytokines and chemokines (45). Given the expression of IL-1H1
in oxazolone-induced CHS, we sought to determine its expression during
HSV-1 infection. Mice were infected with HSV-1 (SC-16) following
scarification of ear pinnae, and ears were collected daily for analysis
of IL-1H1 RNA and protein expression. Ear lesions appeared within 4-5
days following infection and were characterized by degeneration and
necrosis of epithelial cells, dermal edema, and neutrophil and
mononuclear cell infiltrates and the presence of epithelial
intranuclear viral inclusions (data not shown). By Western blot
analysis using an anti-murine IL-1H1-specific antibody, a protein of
~18 kDa, the expected size of IL-1H1, was first detected on day 1 and
increased substantially in intensity by day 6-7 postinfection (Fig.
6). The expression of viral glycoprotein C was first detected on day 2 and increased in intensity at day 4-6
(Fig. 6). Day 8-10 ear samples were negative for both viral antigen
and IL-1H1 (data not shown).
We next performed in situ hybridization studies to localize
the source of IL-1H1 in HSV-1-infected mouse ears. Similar to the data
obtained with the chronic oxazolone model, IL-1H1 mRNA expression
was detected in keratinocytes of the hyperplastic epidermis of
HSV-1-infected mouse ears (Fig.
7C). IL-1H1 mRNA was first detected at day 4 (data not shown) and increased to a maximum at day 7. No expression of IL-1H1 mRNA was detected in control uninfected
mouse ears (Fig. 7A). Several proinflammatory cytokines and
chemokines such as TNF, IL-1, IL-18, IL-6, MIP-2, and KC are expressed
during HSV infection of mouse
ears.3 Since viral infection
results in significant inflammation and necrosis, it is possible that
IL-1H1 expressed and released during this process may contribute to the
inflammation. Alternatively, the finding that maximal expression of
IL-1H1 occurs in the hyperplastic or regenerative stage epithelium
after viral envelope expression or intranuclear viral inclusions have
disappeared suggests that IL-1H1 may play a role in viral clearance
and/or repair processes.
Conclusions--
We have identified four novel homologues of the
IL-1 family. While we do not yet know if these new homologues are
agonists or antagonists, we speculate that IL-1H1, IL-1H2, and IL-1H3
may be antagonists, since they are most similar to IL-1ra in structure and sequence and similarly lack a propeptide sequence. On the other
hand, all three active members of the IL-1 family contain propeptide
regions, and in the case of IL-1
The finding of four novel members of the IL-1 family was made possible
by extensive EST sequencing. With the imminent completion of the
sequence of the human genome, we should soon know the full extent of
the IL-1 family. Like other cytokine families, such as the TNFs and
four-helix bundle cytokines, receptor structures and signaling pathways
tend to be largely conserved while differing in subtle detail. Hence,
one may speculate that these new IL-1s will positively or negatively
modulate NF-
-barrel structure and act on target cells by binding to cell surface
receptors with immunoglobulin-like folds in their extracellular domain. While numerous members of the FGF family have been discovered, the IL-1
family has remained small and outnumbered by IL-1 receptor homologues.
From expressed sequence tag data base searches, we have now identified
four additional IL-1 homologues, IL-1H1, IL-1H2, IL-1H3, and IL-1H4.
Like most other IL-1/FGFs, these proteins do not contain a hydrophobic
leader sequence. IL-1H4 has a propeptide sequence, while IL-1H1,
IL-1H2, and IL-1H3 encode only the mature protein. Circular dichroism
spectra and thermal stability analysis suggest that IL-1H1 folds
similarly to IL-1ra. The novel homologues are not widely expressed in
mammals. IL-1H1 is constitutively expressed only in placenta and the
squamous epithelium of the esophagus. However, IL-1H1 could be induced
in vitro in keratinocytes by interferon-
and tumor
necrosis factor-
and in vivo via a contact
hypersensitivity reaction or herpes simplex virus infection. This
suggests that IL-1H1 may be involved in pathogenesis of immune mediated
disease processes. The addition of four novel IL-1 homologues suggests
that the IL-1 family is significantly larger than previously thought.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
-barrel structure consisting of 12
-strands (1-4). There are
currently 19 members of the FGF family (FGF1-19) (5-7) and four
members of the IL-1 family (IL-1
, IL-1
, IL-1ra, and IL-18) (8,
9). With a few exceptions, most IL-1/FGFs are synthesized as
intracellular proteins without a characteristic hydrophobic leader
peptide but nevertheless are released from cells and act on target
cells by binding and signaling through cell surface receptors. In some cases, such as IL-1
and IL-18, proteolytic cleavage of a precursor form of the protein is required for elaboration of the active form of
the ligand (10-13). The IL-1 and FGF receptors also share structural
homology in their extracellular ligand binding domain, since they both
consist of multiple immunoglobulin-like repeats (3, 4, 14), and this
appears to lead to a similar mode of ligand recognition (15).
-barrel structure and the extensive use of backbone
elements in receptor recognition (3, 4). The distinction in biological
activities reflects differences in the intracellular regions of their
cognate receptors. The FGF receptors encode a tyrosine kinase within
the intracellular domain that is stimulated upon ligand binding and
initiates a signaling cascade that results in cell proliferation. This
contributes to their role in stimulating tissue growth during
development and repair. In contrast, the IL-1 receptors do not encode
any enzymatic activity in their intracellular domains, but upon ligand
binding, they recruit two serine/threonine protein kinases, the
interleukin-1 receptor-associated kinases, through motifs shared with
the highly evolutionarily conserved toll receptor family (16). These
stimulate intracellular signaling pathways, leading to the activation
of NF-
B and AP-1 transcription factors (17, 18) that in turn induce
genes involved in the initiation of immune and inflammatory responses.
Thus, IL-1
and -
stimulate the production of chemokines, cytokines, and adhesion molecules that serve to recruit leukocytes to
sites of infection or injury and initiate an inflammatory response. IL-18 stimulates the production of TH1 helper T cells resulting in a
cell-mediated immune response that can lead to cancer immunity and
delayed type hypersensitivity responses (19).
and IL-1
bind with subnanomolar affinity to the cell surface type I IL-1R and recruit IL-1R accessory protein in order to stimulate target cells (17). Similarly, IL-18 binds
to the IL-18 receptor (IL1rrp) with 20 nM affinity and
recruits the IL-18R accessory protein (20, 21). The activity of both
IL-1 and IL-18 is modulated by the soluble or membrane-bound decoy
receptors, IL-1R type II and IL-18BP, respectively (22, 23). IL-1
activity is also moderated by the presence of a natural receptor
antagonist, IL-1ra, which binds to the type I IL-1R but does not
recruit IL-1RAcP. However, there are some IL-1R-like receptors that
have yet to be paired with ligands, such as ST2/T1 and IL-1rrp2
(24-27). This suggests that there may be additional members of the
IL-1 family. In this paper, we describe the discovery of four novel
members of the IL-1 family and the initial biological and biochemical
characterization of IL-1H1.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
and TNF
were produced at
SmithKline Beecham, and INF
was purchased from R & D Systems
(Minneapolis, MN).
/IFN
-stimulated murine keratinocyte PAM 212 cells.
-D-galactopyranoside at 25 °C for
16 h according to the vendor's recommendations. E. coli cells expressing human and murine IL-1H1 were suspended at a
10:1 ratio in 50 mM Tris-HCl, pH 8, 300 mM
NaCl, 1 mM phenylmethylsulfonyl fluoride. The cells were
lysed and purified using Ni2+-nitrilotriacetic acid resin
according to the manufacturer's instructions (Qiagen, Inc., Valencia,
CA). The His tag was cleaved off by incubating IL-1H1 overnight at room
temperature with factor Xa at a factor Xa/IL-1H1 ratio of 1:100. The
mixture of cleaved and uncleaved proteins was passed over a Superdex 75 sizing column in phosphate-buffered saline (PBS) for final purification
and to remove any endotoxin. Purified proteins were used to immunize
rabbits to generate polyclonal antisera according to standard protocols.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
, IL-1
, and IL-1ra, all of which bind
to the same receptor (Table I). Murine
paralogues of the known IL-1s are typically >60% identical, whereas
murine IL-1H1 is 53.2% identical and 63% similar to human IL-1H1. The closest homologues of murine IL-1H3 are murine IL-1ra (59.1%
similarity, 52.5% identity) and human IL-1ra (54.1% similarity,
47.9% identity). Based on homology, IL-1H3 is a relatively recent
duplication of IL-1ra and is not a paralogue of IL-1H2 or IL-1H4.
Indeed, the likely human orthologue of IL-1H3 (IL-1HY1) was recently
published while this manuscript was in preparation (34). Human IL-1HY1 and murine IL-1H3 are ~90% identical and differ in only few amino acids in the central and C-terminal regions (34). IL-1H4 seems to be
the most distantly related protein to known IL-1s.

View larger version (77K):
[in a new window]
Fig. 1.
Sequence alignment and schematic
representation of various members of the IL-1 family.
A, mature regions of various members of the IL-1 family were
first aligned using the Clustal algorithm of the MEGALIGN program of
Lasergene software (DNASTAR Inc., Madison, WI). The alignment was then
subsequently refined manually. Residues matching the majority are
boxed and shaded. The arrow
bars below the alignment indicate the predicted
-strands for IL-1
and IL-1
that appear to be conserved among
other members. B, various members of the IL-1 family are
represented schematically to show the precursor, mature region, and
cleavage site (arrow) of each protein. In the case of
IL-1ra, the differential splicing using alternate exons is also shown.
Note that IL-1H4 encodes a putative cleavage site similar to IL-1
,
IL-1
, and IL-18. The experimentally determined (arrow)
and putative cleavage site (arrow and question mark) and
flanking sequence for IL-1
, IL-1H4, and IL-18 are also shown.
Percentage of amino acid similarity between various IL-1 family members
, IL-1
, and IL-1ra have been localized, further
supporting an evolutionary relationship within the IL-1 family.
Interestingly, human IL-1H3 (IL-1HY1) was also mapped to chromosome
2q14 in close proximity to IL-1ra (34). The chromosomal localization of
the remaining IL-1 homologues has not yet been determined.
, IL-1
, and IL-1ra (Fig. 1), suggesting
that they most likely retain a similar tertiary structure. In contrast,
IL-1H4 has a significant propeptide region that, like IL-1
and
IL-18, contains a potential proteolytic processing site for caspase 1 (Fig. 1B) that could be necessary for its biological activity. Preliminary data indicate that IL-1H4 is cleaved by caspase 1 at this site.2
(Fig. 2A). The shape and
amplitude of IL-1ra and IL-1
spectra agree well with previous
reports (35, 36). The CD spectrum of IL-1H1 is similar to IL-1ra and
consistent with a substantial contribution from
-strands. The
Tm for thermal denaturation of IL-1H1 was 61 °C,
which is also similar to that for IL-1ra and indicates that the two
proteins have a comparable folding energy (Fig. 2B).
Interestingly, the spectrum of IL-1
is somewhat distinct, although
it also has a similar structure. These data suggest that IL-1H1 is
likely to adopt the characteristic
-barrel structure of the IL-1s.
The position of 12
-strands in the IL-1H1 sequence can be predicted
from the alignment with IL-1
, IL-1
, and IL-1ra, whose structures
are known (see Fig. 1A).

View larger version (22K):
[in a new window]
Fig. 2.
Biophysical characterization of IL-1H1.
A, far-UV circular dichroism spectra of IL-1ra
(dashed), IL-1
(dotted), and IL-1H1
(solid) shown as mean residue ellipticity versus
wavelength. The shapes and amplitudes of the IL-1ra and IL-1
spectra
agreed well with previous reports (35, 36). B, thermal
unfolding stability of IL-1ra (open symbols) and IL-1H1
(closed symbols) shown as the fraction of unfolded cytokine
versus temperature. Unfolding was monitored by ellipticity
at 215 nm. Half-unfolded Tm values determined from
the data in the figure are 59 and 61 °C for IL-1ra and
IL-1H1, respectively.
- and IFN
-stimulated keratinocyte and
epithelial cell cDNA libraries, while the murine orthologue was
found in a placenta library. Similarly, a human IL-1H2 EST was found
only in an osteoclastoma cell library; a mouse IL-1H3 EST was found in
a 19.5-day embryo library; and human IL-1H4 ESTs were found in a mixed
fetal lung, testes, B cell, and colon library. Although we did not
detect any expression of murine IL-1H3 in commercially available murine
multiple tissue Northern blots, its human orthologue, IL-1HY1, was
reported to be expressed in fetal skin and spleen cDNA libraries by
polymerase chain reaction analysis (34).
- and IFN
-treated human keratinocytes with maximal
expression when both cytokines were added together (Fig.
3A, lanes 1-4). A
similar induction was seen in the epithelial cell line, A431 (Fig.
3A, lanes 5 and 6). Similar to IL-1H1
and consistent with stimulus-dependent expression of these
genes, human IL-1H3 (IL-1HY1) was shown to be induced in response to
phorbol esters and bacterial lipopolysaccharide (34).

View larger version (40K):
[in a new window]
Fig. 3.
Expression of IL-1H1 mRNA and
protein. A, total RNA was prepared from primary human
keratinocytes (lanes 1-4) and A431 epithelial cells
(lanes 5 and 6) that were either untreated
(C) or treated with 20 ng/ml of either TNF
(T), IFN
(I), or TNF
and IFN
together
(T+I). The expression of human IL-1H1 mRNA was analyzed
by Northern blot. The locations of IL-1H1, GAPDH, and 18 S RNA are
shown. B, the expression of human IL-1H1 protein was
analyzed in cell lysates (Cell) and conditioned media
(Media) from similarly treated cells as in A. The
results of an immunoprecipitation (lanes 1-8) and
immunoblot (lanes 9-12) are shown. The locations of 21- and
14-kDa molecular mass markers and IL-1H1 (arrow) are
indicated.
and IFN
(Fig. 3B), as seen in the mRNA experiments. However, the protein was only detected in the cell lysates and not in the conditioned media. Intracellular expression of IL-1H1 protein was also detected in bacterial
lipopolysaccharide-stimulated human monocytes (data not shown).
Keratinocytes have been shown to contain IL-1ra and precursor forms of
IL-1
and IL-1
that remain in cells and are released into the
extracellular environment after damage and lysis of cells (37-39). A
similar mechanism may also apply to IL-1H1.
and
IFN
and minimal levels of IL-4, but after 4 weeks, the cytokine
profile converts to a TH2 immune response as evidenced by increased
IL-4 and decreased IFN
and TNF
mRNA (30). Histological
analysis of mouse ears chronically exposed to oxazolone revealed
hyperplastic epithelium, thickening of subepithelium, and infiltration
by neutrophils, eosinophils, and lymphocytes (Ref. 30; data not shown).
In contrast to the results seen with acute oxazolone treatment, a
4-week chronic oxazolone treatment led to a significant induction of
IL-1H1 RNA (Fig. 4A, lanes 3 and
4).

View larger version (42K):
[in a new window]
Fig. 4.
Expression of mouse IL-1H1 in
murine ear by oxazolone-induced CHS. A, mouse
ears were exposed to UVB (UV) radiation or treated topically
with oxazolone in acute (OX/A) or chronic (OX/C) mode as
described under "Materials and Methods." Total RNA was isolated
from mouse ears and analyzed for IL-1H1 expression. RNA from normal
(N) untreated ears is shown in lane 1. The
locations of IL-1H1, 18 S RNA, and GAPDH are indicated. B,
mouse ears were treated with an acute (OX/A) or chronic
(OX/C) regimen of oxazolone. Total RNA was isolated at 3, 6, and 24 h after the final oxazolone challenge and analyzed for
IL-1H1, IL-4, and GAPDH expression. RNA from normal (N)
untreated ears is shown in lane 1.

View larger version (71K):
[in a new window]
Fig. 5.
Expression of IL-1H1 in chronically
oxazolone-treated mouse ears. Representative tissue sections
(n = 6) from ears of oxazolone-treated (A
and B) or control mice (C and D) were
hybridized with murine IL-1H1 antisense (A and C)
or sense (B and D) riboprobes. A strong
hybridization signal (white grains) was detected
using the murine IL-1H1 antisense riboprobe localized in the
hyperplastic epithelium of ears from oxazolone-sensitized mice
(A). No signal was detected in ears of untreated mice
(C) or with sense probes (B and D).
Magnification is × 100.
null mouse and a mouse
overexpressing type II IL-1R argue that IL-1
and/or IL-1
are not
essential for the oxazolone-induced CHS response, suggesting the
involvement of additional factors such as IL-1H1 (44).

View larger version (31K):
[in a new window]
Fig. 6.
Expression of IL-1H1 protein in
HSV-1-infected mouse ears. Representative individual ears
(n = 4) isolated from uninfected (U) or
HSV-1 (SC-16)-infected mice were isolated at varying times
postinfection. Protein extracts were analyzed by immunoblot analysis
with HSV glycoprotein C-specific antibodies (1:5000 dilution) or
anti-IL1H1 (1:1000). Blots were developed using ECL reagent (Amersham
Pharmacia Biotech).

View larger version (78K):
[in a new window]
Fig. 7.
Expression of IL-1H1 mRNA in
HSV-1-infected mouse ears. Representative tissue sections from
ears (n = 4) of control (A and B)
or HSV-infected mice (C and D) at day 7 were
hybridized with murine IL-1H1 antisense (A and C)
or sense (B and D) riboprobes. A strong
hybridization signal (white grains) was detected
using the mouse IL-1H1 antisense riboprobe in keratinocytes in the
hyperplastic epithelium of ears from HSV-infected mice (C).
No signal was detected in the ears of untreated mice (A) or
with sense probes (D). Magnification is × 135.
and IL-18 this region must be
proteolytically released for full biological activity. Since IL-1H4 has
a potential propeptide region and a caspase 1 cleavage site, we
speculate that it is an agonist.
B and AP-1 signaling stimulated through IL-1R-associated
kinase/TNF receptor-associated factor-like complexes recruited through
the IL-1R family (18). The next step will be to identify the receptors,
signaling pathways, and biological activities of these new IL-1
homologues and appropriate stimulation conditions and tissues where
they are expressed.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Annalisa Hand, Cheng Zou, and Jim Alston for expert technical assistance; Genetic Technologies for nucleotide synthesis and DNA sequencing; Wendy Crowell for preparation of the figures; and Drs. Maxine Gowen, John Lee, Lisa Marshall, and Michael Lotze for support and critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF200492 (human IL-1H1), AF200493 (mouse IL-1H1), AF200494 (human IL-1H2), AF200495 (mouse IL-1H3), and AF200496 (human IL-1H4).
b To whom correspondence should be addressed: UW 2109, P.O. Box 1539, 709 Swedeland Rd., King of Prussia, PA 19406-0939. Tel.: 610-270-7245; Fax: 610-270-5598; E-mail: Sanjay_Kumar@SBPHRD.COM.
d Present Address: Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320-1799.
k Present Address: Cardiovascular Diseases, DuPont Pharmaceuticals, Experimental Station, E400/3257, Route 141 and Henry Clay Rds., Wilmington, DE 19880-0400.
2 S. Kumar, unpublished data.
3 R. Tal-Singer, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IL, interleukin; IL-1H, IL-1 homologue; IL-1R, IL-1 receptor; TNF, tumor necrosis factor; IFN, interferon; CHS, contact hypersensitivity; HSV, herpes simplex virus; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PBS, phosphate-buffered saline; FGF, fibroblast growth factor; EST, expressed sequence tag.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Priestle, J. P.,
Schaer, H. P.,
and Gruetter, M. G.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
9667-9671 |
| 2. |
Zhu, X.,
Komiya, H.,
Chirino, A.,
Faham, S.,
Fox, G. M.,
Arakawa, T.,
Hsu, B. T.,
and Rees, D. C.
(1991)
Science
251,
90-93 |
| 3. | Vigers, G. P. A., Anderson, L. J., Caffes, P., and Brandhuber, B. J. (1997) Nature 386, 190-194[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Schreuder, H., Tardif, C., Trump-Kallmeyer, S., Soffientini, A., E., S., Akeson, A., Bowlin, T., Yanofsky, S., and Barrett, R. W. (1997) Nature 386, 194-200[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Xu, X. L., Weinstein, M., Li, C. L., and Deng, C. X. (1999) Cell Tissue Res. 296, 33-43[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Nishimura, T., Utsunomiya, Y., Hoshikawa, M., Ohuchi, H., and Itoh, N. (1999) Biochim. Biophys. Acta 1444, 148-151[Medline] [Order article via Infotrieve] |
| 7. |
Ohbayashi, N.,
Hoshikawa, M.,
Kimura, S.,
Yamasaki, M.,
Fukui, S.,
and Itoh, N.
(1998)
J. Biol. Chem.
273,
18161-18164 |
| 8. | Dinarello, C. A. (1994) FASEB J. 8, 1314-1325[Abstract] |
| 9. | Dinarello, C. A., Novick, D., Puren, A. J., Fantuzzi, G., Shapiro, L., Muhl, H., and Yoon, D. Y. (1998) J. Leukocyte Biol. 63, 658-664[Abstract] |
| 10. |
Hazuda, D.,
Webb, R. L.,
Simon, P.,
and Young, P.
(1989)
J. Biol. Chem.
264,
1689-1693 |
| 11. |
Cerretti, D. P.,
Kozlosky, C. J.,
Mosley, B.,
Nelson, N.,
Van Ness, K.,
Greenstreet, T. A.,
March, C. J.,
Kronheim, S. R.,
Druck, T.,
Cannizzaro, L. A.,
Huebner, K.,
and Black, R. A.
(1992)
Science
256,
97-100 |
| 12. | Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Elliston, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J.-F., Egger, L. A., Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T.-T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) Nature 356, 768-774[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Gu, Y.,
Kuida, K.,
Tsutsui, H.,
Ku, G.,
Hsiao, K.,
Fleming, M. A.,
Hayashi, N.,
Higashino, K.,
Okamura, H.,
Nakanishi, K.,
Kurimoto, M.,
Tanimoto, T.,
Flavell, R. A.,
Sato, V.,
Harding, M. W.,
Livingston, D. J.,
and Su, M. S.-S.
(1997)
Science
275,
206-209 |
| 14. | Zhang, Y., Gorry, M. C., Post, J. C., and Ehrlich, G. D. (1999) Gene (Amst.) 230, 69-79[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., and Mohammadi, M. (1999) Cell 98, 641-50[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Rock, F. L.,
Hardiman, G.,
Timans, J. C.,
Kastelein, R. A.,
and Bazan, J. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
588-593 |
| 17. | O'Neill, L. A., and Greene, C. (1998) J. Leukocyte Biol. 63, 650-657[Abstract] |
| 18. | Auron, P. E. (1998) Cytokine Growth Factor Rev. 9, 221-237[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukuda, Y., Hattori, K., Akita, K., Namba, M., Tanabe, F., Konishi, K., Fukuda, S., and Kurimoto, M. (1995) Nature 378, 88-91[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Torigoe, K.,
Ushio, S.,
Okura, T.,
Kobayashi, S.,
Taniai, M.,
Kunikata, T.,
Murakami, T.,
Sanou, O.,
Kojima, H.,
Fujii, M.,
Ohta, T.,
Ikeda, M.,
Ikegami, H.,
and Kurimoto, M.
(1998)
J. Biol. Chem.
272,
25737-25742 |
| 21. |
Born, T. L.,
Thomassen, E.,
Bird, T. A.,
and Sims, J. E.
(1998)
J. Biol. Chem.
273,
29445-29450 |
| 22. | McMahan, C. J., Slack, J. L., Mosley, B., Cosman, D., Lupton, S. D., Brunton, L. L., Grubin, C. E., Wignall, J. M., Jenkins, N. A., Brannan, C. I., Copeland, N. G., Huebner, K., Croce, C. M., Cannizzaro, L. A., Benjamin, D., Dower, S. K., Spriggs, M. K., and Sims, J. E. (1991) EMBO J. 10, 2821-2832[Medline] [Order article via Infotrieve] |
| 23. | Novick, D., Kim, S. H., Fantuzzi, G., Reznikov, L. L., Dinarello, C. A., and Rubinstein, M. (1999) Immunity 10, 127-136[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Tominaga, S. (1989) FEBS Lett. 258, 301-304[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Klemenz, R.,
Hoffmann, S.,
and Werenskiold, A. K.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
5708-5712 |
| 26. |
Kumar, S.,
Minnich, M. D.,
and Young, P. R.
(1995)
J. Biol. Chem.
270,
27905-27913 |
| 27. | Lovenberg, T. W., Crowe, P. D., Liu, C. L., Chalmers, D. T., Liu, X. J., Liaw, C., Clevenger, W., Oltersdorf, T., Desouza, E. B., and Maki, R. A. (1996) J. Neuroimmunol. 70, 113-122[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) Protein Sci. 4, 2411-2423[Abstract] |
| 29. | Eisenberg, R. J., Ponce de Leon, M., Friedman, H. M., Fries, L. F., Frank, M. M., Hasting, J. C., and Cohen, G. H. (1987) Microb. Pathog. 3, 423-435[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Webb, E. F., Tzimas, M. N., Newsholme, S. J., and Griswold, D. E. (1998) J. Invest. Dermatol. 111, 86-92[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Griswold, D. E., Connor, J. E., Dalton, B. J., Lee, J. C., Simon, P., Hillegass, L., Sieg, D. J., and Hanna, N. (1991) J. Invest. Dermatol. 97, 1019-1023[CrossRef][Medline] [Order article via Infotrieve] |
| 32. |
Hill, T. J.,
Field, H. J.,
and Blyth, W. A.
(1975)
J. Gen. Virol.
28,
341-353 |
| 33. | Lu, L., and Gillet, N. A. (1994) Cell Vis. 1, 169-176 |
| 34. | Mulero, J. J., Pace, A. M., Nelkin, S. T., Loeb, D. B., Correa, T. R., Drmanac, R., and Ford, J. E. (1999) Biochem. Biophys. Res. Commun. 263, 702-706[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Chang, B. S.,
Beauvais, R. M.,
Arakawa, T.,
Narhi, L. O.,
Dong, A. C.,
Aparisio, D. I.,
and Carpenter, J. F.
(1996)
Biophys. J.
71,
3399-3406 |
| 36. |
Meyers, C. A.,
Johanson, K. O.,
Miles, L. M.,
McDevitt, P. J.,
Simon, P. L.,
Webb, R. L.,
Chen, M.-J.,
Holskin, B. P.,
Lillquist, J. S.,
and Young, P. R.
(1987)
J. Biol. Chem.
262,
11176-11181 |
| 37. | Mizutani, H., Black, R., and Kupper, T. S. (1991) J. Clin. Invest. 87, 1066-1071 |
| 38. |
Haskill, S.,
Martin, G.,
Van Le, L.,
Morris, J.,
Peace, A.,
Bigler, C. F.,
Jaffe, G. J.,
Hammerberg, C.,
Sporn, S. A.,
Fong, S.,
Arend, W. P.,
and Ralph, P.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3681-3685 |
| 39. |
Kupper, T. S.,
Ballard, D. W.,
Chua, A. O.,
McGuire, J. S.,
Flood, P. M.,
Horowitz, M. C.,
Langdon, R.,
Lightfoot, L.,
and Gubler, U.
(1986)
J. Exp. Med.
164,
2095-2100 |
| 40. | Kumar, S., Tzimas, M. N., Griswold, D. E., and Young, P. R. (1997) Biochem. Biophys. Res. Commun. 235, 474-478[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Shortnick, L. P.,
de Tongi, P.,
Mariathasan, S.,
Goellner, J.,
Strauss- Schoenberg, J.,
Karr, R. W.,
Ferguson, T. A.,
and Chaplin, D. D.
(1996)
J. Exp. Med.
183,
1427-1436 |
| 42. | Enk, A. H., Angelino, V. L., Udey, M. C., and Katz, S. I. (1993) J. Immunol. 150, 3698-3704[Abstract] |
| 43. | Zheng, H., Fletcher, D., Kozak, W., Jiang, M., Hofman, K. J., Conn, C. A., Soszynski, D., Grabiec, C., Trumbauer, M. E., Shaw, A., Kostura, M. J., Stevens, K., Rosen, H., North, R. J., Chen, H. Y., Tocci, M. J., Kluger, M. J., and Van der Ploeg, T. S. (1995) Immunity 3, 9-19[CrossRef][Medline] [Order article via Infotrieve] |
| 44. |
Rauschmayr, T.,
Groves, R. W.,
and Kupper, T. S.
(1997)
Proc. Natl. Acad. Sci., U. S. A.
94,
5814-5819 |
| 45. | Mikloska, Z., Danis, V. A., Adams, S., Lloyd, A. R., Adrian, D. L., and Cunningham, A. L. (1998) J. Infect. Dis. 177, 827-838[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. Blumberg, H. Dinh, E. S. Trueblood, J. Pretorius, D. Kugler, N. Weng, S. T. Kanaly, J. E. Towne, C. R. Willis, M. K. Kuechle, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation J. Exp. Med., October 29, 2007; 204(11): 2603 - 2614. [Abstract] [Full Text] [PDF] |
||||
![]() |
M B Resnick, E Sabo, P A Meitner, S S Kim, Y Cho, H K Kim, R Tavares, and S F Moss Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo Gut, December 1, 2006; 55(12): 1717 - 1724. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A Dinarello Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process Am. J. Clinical Nutrition, February 1, 2006; 83(2): 447S - 455S. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fukushima, Y. Ikehara, and K. Yamashita Functional Role Played by the Glycosylphosphatidylinositol Anchor Glycan of CD48 in Interleukin-18-induced Interferon-{gamma} Production J. Biol. Chem., May 6, 2005; 280(18): 18056 - 18062. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Towne, K. E. Garka, B. R. Renshaw, G. D. Virca, and J. E. Sims Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-{kappa}B and MAPKs J. Biol. Chem., April 2, 2004; 279(14): 13677 - 13688. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Azam, D. Novick, P. Bufler, D.-Y. Yoon, M. Rubinstein, C. A. Dinarello, and S. H. Kim Identification of a Critical Ig-Like Domain in IL-18 Receptor {alpha} and Characterization of a Functional IL-18 Receptor Complex J. Immunol., December 15, 2003; 171(12): 6574 - 6580. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mandinova, R. Soldi, I. Graziani, C. Bagala, S. Bellum, M. Landriscina, F. Tarantini, I. Prudovsky, and T. Maciag S100A13 mediates the copper-dependent stress-induced release of IL-1{alpha} from both human U937 and murine NIH 3T3 cells J. Cell Sci., July 1, 2003; 116(13): 2687 - 2696. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mandinov, A. Mandinova, S. Kyurkchiev, D. Kyurkchiev, I. Kehayov, V. Kolev, R. Soldi, C. Bagala, E. D. de Muinck, V. Lindner, et al. Copper chelation represses the vascular response to injury PNAS, May 27, 2003; 100(11): 6700 - 6705. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Gao, S. Kumar, M. T. Lotze, C. Hanning, P. D. Robbins, and A. Gambotto Innate Immunity Mediated by the Cytokine IL-1 Homologue 4 (IL-1H4/IL-1F7) Induces IL-12-Dependent Adaptive and Profound Antitumor Immunity J. Immunol., January 1, 2003; 170(1): 107 - |